Top 18 Attenua investors
The most complete profiles first. Showing 18 of 18.
Annie MitsakVerified
Venture Capital, Investor · United States
SeedHealth CareGeneticsWomen FoundedLife SciencePortfolio: FoRx Therapeutics, Santaris Pharma, Spruce Biosciences, Attenua and 70 more
Verified email available
Ken HaasVerified
Venture Capital, Advisor, Investor · United States
Series BHealth CareWomen FoundedLife ScienceBiotechnologyPortfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more
Verified email available
andrew sinclairVerified
Venture Capital, Private Equity Firm, Investor · United Kingdom
Series BHealth CareWomen FoundedLife ScienceBiotechnologyPortfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more
Verified email available
AnneVerified
Venture Capital · United States
Health CareGeneticsWomen FoundedLife SciencePortfolio: FoRx Therapeutics, Santaris Pharma, Spruce Biosciences, Attenua and 70 more
Verified email available
Paulina HillVerified
Venture Capital · United States
Health CareGeneticsWomen FoundedLife SciencePortfolio: FoRx Therapeutics, Santaris Pharma, Spruce Biosciences, Attenua and 70 more
Verified email available
Rob FaulknerVerified
Hedge Fund, Venture Capital, Private Equity Firm · United States
Health CareHospitalsGeneticsWomen FoundedPortfolio: Lifesprout, Blueprint Medicines, OncoResponse, CorVent Medical and 73 more
Contact details available
Shelley ChuVerified
Venture Capital · United States
Health CareWomen FoundedLife ScienceBiotechnologyPortfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more
Verified email available
Tim HainesVerified
Venture Capital · United Kingdom
Health CareWomen FoundedLife ScienceBiotechnologyPortfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more
Verified email available
Bali Muralidhar
Venture Capital, Private Equity Firm, Investor · United Kingdom
Series BHealth CareWomen FoundedLife ScienceBiotechnologyPortfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 69 more
Contact details available
Brian Gallagher, Jr.
Venture Capital, Investor · United States
Series BHealth CareWomen FoundedLife ScienceBiotechnologyPortfolio: Kesios Therapeutics, Spruce Biosciences, Aileron Therapeutics, Amarin and 67 more
Contact details available
Francesco Draetta
Venture Capital, Investor · United States
SeedHealth CareGeneticsWomen FoundedLife SciencePortfolio: FoRx Therapeutics, Santaris Pharma, Spruce Biosciences, Attenua and 70 more
Contact details available
Katie Kerfoot
Venture Capital, Investor · United States
SeedHealth CareGeneticsWomen FoundedLife SciencePortfolio: FoRx Therapeutics, Santaris Pharma, Spruce Biosciences, Attenua and 70 more
Contact details available
Kurt von Emster
Venture Capital, Private Equity Firm, Investor · United States
Series BHealth CareWomen FoundedInvestment ManagementLife SciencePortfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more
Contact details available
Michelle Doig
Venture Capital, Investor · Canada
SeedHealth CareGeneticsWomen FoundedLife SciencePortfolio: FoRx Therapeutics, Santaris Pharma, Spruce Biosciences, Attenua and 70 more
Contact details available
Vin Miles
Venture Capital, Investor · United States
Series BHealth CareWomen FoundedLife ScienceBiotechnologyPortfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more
Contact details available
Gerard van Hamel Platerink
Hedge Fund, Venture Capital, Private Equity Firm · United States
Health CareGeneticsWomen FoundedLife SciencePortfolio: Lifesprout, Blueprint Medicines, OncoResponse, CorVent Medical and 73 more
Contact details available
John Heard
Venture Capital, Private Equity Firm · United Kingdom
Health CareWomen FoundedLife ScienceBiotechnologyPortfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more
Contact details available
Sarah Shackelton
Venture Capital · United Kingdom
Health CareWomen FoundedLife ScienceBiotechnologyPortfolio: Kesios Therapeutics, Spruce Biosciences, Amarin, Syntaxin and 64 more
Contact details available
By investment stage
By location
Related industries
Most-backed portfolio companies
- Median Technologies16
- Scorpion Therapeutics16
- Oxagen16
- IFM Therapeutics16
- Paratek Pharmaceuticals16
- Spruce Biosciences16
- Dicerna Pharmaceuticals16
- Proteon Therapeutics10
- Realm Therapeutics10
- Nouscom10
- PrimeraDx (Primera Biosystems)10
Frequently asked questions
How many Attenua investors are on Angel Roster?
Angel Roster lists 18 Attenua investors. 7 of them (39%) include a verified email address.
What types of investors are they?
The most common investor types are Venture Capital Firms (18), Private Equity Firms (6) and Hedge Funds (2). An investor can have more than one type, for example an angel who is also a venture partner.
Which stages do Attenua investors invest in?
Among those that list a stage, the most common are Series B (6) and Seed (4).
Where are Attenua investors based?
Most are based in the United States (12), the United Kingdom (5) and Canada (1).
Which companies have Attenua investors backed?
The most-backed portfolio companies among them are Median Technologies (16), Scorpion Therapeutics (16), Oxagen (16), IFM Therapeutics (16) and Paratek Pharmaceuticals (16).
How do I contact Attenua investors?
Create a free Angel Roster account to search and filter all 18, then unlock verified emails and LinkedIn profiles on a paid plan. Every plan starts with a 3-day free trial.